ClinicalTrials.gg
CompletedNCT07345130Updated Sep 23, 2026

A Bioequivalence Study of Advil Tablet (Mini) (Ibuprofen 200 mg) Versus Advil Tablet (Ibuprofen 200 mg) in Healthy Adult Subjects Under Fasted Conditions and Bioavailability Assessment of Advil Tablet (Mini) Under Fed Conditions

A Phase 1 interventional study of Advil Tablet (Mini) (Test Product) and Advil Tablet (Reference Product) in Bioequivalence and Bioavailability, sponsored by HALEON. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by HALEON · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to assess the bioequivalence of Advil Tablet (Mini) (Test Product) to Advil Tablet (Reference Product) under fasted conditions and to characterize the impact of food on the bioavailability of the Test Product under fed conditions.

Read the detailed description

This will be a randomized, open-label, single-center, single-dose, three-treatment, three-period, six sequence crossover bioequivalence and bioavailability (food effect) study in healthy adult participants with at least a 3-day washout period between treatment administrations. A sufficient number of participants will be screened to randomize approximately 50 participants, to ensure that at least 42 evaluable participants complete the entire study. Participants will be randomly assigned to one of six treatment sequences and will receive a single dose of each (of 3) treatments in each (of 3) periods following a crossover design. Blood will be sampled regularly at scheduled times for 24 hours following treatment in each period to assess the pharmacokinetic parameters.

02

Conditions studied

  • Bioequivalence
  • Bioavailability
03

In context

Lead sponsor

HALEON is the lead sponsor of 65 studies on the registry; 10 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant provision of a signed and dated form (ICF) indicating that the participant has been informed of all pertinent aspects of the study before any assessment is performed.
  • A participant whose biological sex at birth is male or female.
  • A participant who is 18 to 55 years of age inclusive, at the signing of the ICF.
  • A participant who is willing and able to comply with scheduled visits, treatment plan, laboratory tests, study restrictions and other study procedures.
  • A participant in good general and mental health with, in the opinion of the Investigator or medically qualified designee, no or relevant abnormalities in medical history or upon physical examination, vital sign measurements, 12-lead (ECG) or clinical laboratory tests, or condition, that would impact the participant 's safety, well-being or the outcome of the study, if they were to participate in the study, or affect the individual's ability to understand and follow study procedures and requirements.
  • A participant with a (BMI) of between 18.5 and 30.0 kilogram per meter square (kg/m\^2); and a total body weight more than or equal to (>=) 50.0 kg for males and >=45.0 kg for females.
  • A female participant of and at risk for pregnancy must agree to use a highly effective method of throughout the study and for at least 30 days after the last dose of assigned treatment. A female participant who is not of childbearing potential must meet at least one of the following criteria:

    1. Has achieved status, defined as cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; and have a serum follicle-stimulating hormone (FSH) level >=40 milli-international units per milliliter (mIU/mL).
    2. Has undergone a documented (including self-reported) hysterectomy and/or bilateral oophorectomy.

Exclusion criteria

Exclusion Criteria:

  • A participant who is an employee of the site, either directly involved in the conduct of the study or a member of their immediate family; or an employee of the investigational site otherwise supervised by the Investigator; or a Haleon employee directly involved in the conduct of the study or a member of their immediate family.
  • A participant who has participated in other studies (including non-medicinal studies) involving investigational product(s) within 30 days prior to study entry and/or during study participation.
  • A participant with, in the opinion of the Investigator or medically qualified designee, an acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator or medically qualified designee, would make the participant inappropriate for entry into this study.
  • A female participant who is pregnant (as confirmed by a positive pregnancy test) or intending to become pregnant over the duration of the study.
  • A female participant who is breastfeeding.
  • A participant with known or suspected intolerance or to the study materials (or closely related compounds) or any of their stated ingredients.
  • A participant with any history of asthma, urticaria, or other significant allergic diathesis or allergic reaction to any other pain reliever/fever reducer (example, aspirin or other non-steroidal anti-inflammatory drugs [NSAIDs]). Childhood asthma may be acceptable at the discretion of the Investigator. A participant with uncomplicated seasonal allergic rhinitis can be accepted if expected allergy season is clearly outside enrollment/treatment period.
  • A participant with a diagnosis of long syndrome or QTcF greater than (>)450 millisecond (msec) for males and >470 msec for females at screening.
  • A participant with vital sign abnormalities (systolic blood pressure lower than 90 or over 140 millimeter of mercury (mmHg), diastolic blood pressure lower than 50 or over 90 mmHg, or pulse rate less than 50 or over 100 beats per minute [bpm]).
  • A participant unwilling or unable to comply with Lifestyle Considerations described in this protocol.
  • A participant who has used any medication (including over the counter [OTC] medications and herbal remedies) within 2 weeks or within less than 10 times the elimination half-life of the respective drug (whichever is longer) before first scheduled study drug administration or is anticipated to require any concomitant medication during that period or at any time throughout the study. Allowed treatments are:

    1. systemic and hormone replacement therapy, as long as female participant is on stable treatment for at least 3 months before first scheduled study drug administration and continues treatment throughout the study.
    2. occasional use of acetaminophen (up to 2 gram [g] daily).
  • A participant with evidence or history of clinically significant laboratory abnormality, hematological, renal, endocrine, pulmonary, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease within the last 5 years that may increase the risk associated with study participation, in the opinion of the Investigator or medically qualified designee.
  • A participant with clinically relevant chronic or acute infectious illnesses or febrile infections within two weeks prior to start of the study.
  • A participant who has had any surgical or medical condition which may significantly alter the absorption, distribution, metabolism or excretion of any drug substance.
  • A participant with signs and symptoms suggestive of Corona virus disease (COVID)-19 as defined by World Health Organization (WHO) or local guidance (example, fever, cough, etc.) within 14 days prior to the first dose.
  • A participant with known COVID-19 positive contacts in the past 14 days.
  • A participant who has received any vaccination, including a COVID-19 vaccine, within 14 days prior to the first dose.
  • A participant with a history of drug abuse within 1 year prior to screening, or recreational use of soft drugs (such as marijuana) within 1 month, or hard drugs (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and amphetamine derivatives) within 3 months prior to screening.
  • A participant with a history of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 10 units for women or 15 units for men of alcohol per week (1 unit = 340 mL of beer 5 percent [%], 140 mL of wine 12%, or 45 mL of distilled alcohol 40%).
  • A participant with a positive drug screen, alcohol test, or cotinine test.
  • A participant who is a current smoker, defined as the use of tobacco or nicotine products during the 3 months prior to screening until admission to the unit or a positive urine cotinine test at screening.
  • A participant who reports regular consumption of beverages or food containing xanthine derivatives or xanthine-related compounds (example, coffee, tea, caffeine-containing sodas and chocolate), equivalent to >=500 mg xanthine per day.
  • A participant who reports consumption of any drug metabolizing enzyme (example, or other cytochrome P450 enzymes) inducing or inhibiting aliments, or aliments which have an effect on the P-glycoprotein (PGP) efflux pump (example, beverages or food supplements including broccoli, Brussels sprouts, grapefruit, grapefruit juice, star fruit, pineapple, mango, papaya, St. John's Wort etc.) within 2 weeks prior to admission to the unit.
  • A participant with a history of long-term treatment with carbamazepine, phenobarbitone, phenytoin, primidone, rifampicin, St John's Wort or other drugs that induce liver enzymes.
  • A participant with positive results in any of the serology tests for human immune deficiency () antigen and antibody, virus (HCV)-antibody (Ab), serum antigen (HBsAg) and HBc-Ab (immunoglobulin [Ig]G + IgM).
  • A participant who has performed strenuous physical exercise (body building, high performance sports) from within 2 weeks prior to admission and who does not agree to refrain from strenuous physical exercise throughout the entire study.
  • A participant with an allergy to skin disinfecting agents, tape, or latex rubber, whenever appropriate substitutions cannot be applied or in the Investigator's opinion may pose a risk to the participant.
  • A participant with any condition not identified in the protocol that in the opinion of the Investigator would confound the evaluation and interpretation of the study data or may put the participant at risk.
  • A participant who has donated plasma within 7 days prior to first dosing, or who has donated or lost 500 mL or more of whole blood within 8 weeks prior to first dosing.
  • A participant with veins unsuitable for repeated venipuncture, as assessed at screening by the Investigator or suitably qualified designee.
  • A participant who, in the opinion of the Investigator or medically qualified designee, should not participate in the study.
  • A participant who has previously been enrolled in this study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Sequence 1: Treatment A/ Treatment B/ Treatment C

    Participants will receive a single oral dose of Advil (Mini) tablet under fasted conditions on Day 1 of Period 1 (Treatment A), followed by a single oral dose of Advil tablet under fasted conditions on Day 1 of Period 2 (Treatment B), followed by a single oral dose of Advil (Mini) under fed conditions, on Day 1 of Period 3 (Treatment C). There will be a washout period of at least 3 days between each treatment.

    Drug: Advil Tablet (Mini) (Test Product) · Drug: Advil Tablet (Reference Product)

  • Experimental
    Sequence 2: Treatment B/ Treatment C/ Treatment A

    Participants will receive a single oral dose of Advil tablet under fasted conditions on Day 1 of Period 1 (Treatment B), followed by a single oral dose of Advil (Mini) under fed conditions, on Day 1 of Period 2 (Treatment C), followed by a single oral dose of Advil (Mini) tablet under fasted conditions on Day 1 of Period 3 (Treatment A). There will be a washout period of at least 3 days between each treatment.

    Drug: Advil Tablet (Mini) (Test Product) · Drug: Advil Tablet (Reference Product)

  • Experimental
    Sequence 3: Treatment C/ Treatment A/ Treatment B

    Participants will receive a single oral dose of Advil (Mini) under fed conditions, on Day 1 of Period 1 (Treatment C), followed by a single oral dose of Advil (Mini) tablet under fasted conditions on Day 1 of Period 2 (Treatment A), followed by a single oral dose of Advil tablet under fasted conditions on Day 1 of Period 3 (Treatment B). There will be a washout period of at least 3 days between each treatment.

    Drug: Advil Tablet (Mini) (Test Product) · Drug: Advil Tablet (Reference Product)

  • Experimental
    Sequence 4: Treatment A/ Treatment C/ Treatment B

    Participants will receive a single oral dose of Advil (Mini) tablet under fasted conditions on Day 1 of Period 1 (Treatment A), followed by a single oral dose of Advil (Mini) under fed conditions, on Day 1 of Period 2 (Treatment C), followed by a single oral dose of Advil tablet under fasted conditions on Day 1 of Period 3 (Treatment B). There will be a washout period of at least 3 days between each treatment.

    Drug: Advil Tablet (Mini) (Test Product) · Drug: Advil Tablet (Reference Product)

  • Experimental
    Sequence 5: Treatment B/ Treatment A/ Treatment C

    Participants will receive a single oral dose of Advil tablet under fasted conditions on Day 1 of Period 1 (Treatment B), followed by a single oral dose of Advil (Mini) tablet under fasted conditions on Day 1 of Period 2 (Treatment A), followed by a single oral dose of Advil (Mini) under fed conditions on Day 1 of Period 3 (Treatment C). There will be a washout period of at least 3 days between each treatment.

    Drug: Advil Tablet (Mini) (Test Product) · Drug: Advil Tablet (Reference Product)

  • Experimental
    Sequence 6: Treatment C/ Treatment B/ Treatment A

    Participants will receive a single oral dose of Advil (Mini) under fed conditions on Day 1 of Period 1 (Treatment C), followed by a single oral dose of Advil tablet under fasted conditions on Day 1 of Period 2 (Treatment B), followed by a single oral dose of Advil (Mini) tablet under fasted conditions on Day 1 of Period 3 (Treatment A). There will be a washout period of at least 3 days between each treatment.

    Drug: Advil Tablet (Mini) (Test Product) · Drug: Advil Tablet (Reference Product)

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Post-dose Concentration (Cmax) Under Fasted Conditions (Test Versus (vs) Reference Product)

    Cmax is defined as the maximum observed post-dose concentration obtained without interpolation. Blood samples will be collected at indicated timepoints for the analysis of Cmax.

    Time frame: Pre-dose (within 1 hour prior to dosing) and at 5,10,15,30,45 minutes and 1,1.25,1.5,1.75,2,2.25,2.5,2.75,3,3.25,3.5,3.75,4,4.25,4.5,4.75,5,5.5,6,8,10,12,16 and 24 hours post-dose on Day 1 in each treatment period (each treatment period is 3 days)

  2. Area Under the Plasma Concentration Versus Time Curve Calculated from Time 0 to the Last Measurable Sampling Time Point, t (AUC[0-t]) Under Fasted Conditions (Test Vs Reference Product)

    AUC(0-t) is defined as the area under the plasma concentration versus time curve calculated from time 0 to the last measurable sampling time point, t, computed using the linear trapezoidal rule. Blood samples will be collected at indicated timepoints for the analysis of AUC(0-t).

    Time frame: Pre-dose (within 1 hour prior to dosing) and at 5,10,15,30,45 minutes and 1,1.25,1.5,1.75,2,2.25,2.5,2.75,3,3.25,3.5,3.75,4,4.25,4.5,4.75,5,5.5,6,8,10,12,16 and 24 hours post-dose on Day 1 in each treatment period (each treatment period is 3 days)

  3. Cmax for Test Product Under Fed Conditions Compared to Fasted Conditions

    Cmax is defined as the maximum observed post-dose concentration obtained without interpolation. Blood samples will be collected at indicated timepoints for the analysis of Cmax.

    Time frame: Pre-dose (within 1 hour prior to dosing) and at 5,10,15,30,45 minutes and 1,1.25,1.5,1.75,2,2.25,2.5,2.75,3,3.25,3.5,3.75,4,4.25,4.5,4.75,5,5.5,6,8,10,12,16 and 24 hours post-dose on Day 1 in each treatment period (each treatment period is 3 days)

  4. AUC(0-t) for Test Product Under Fed Conditions Compared to Fasted Conditions

    AUC(0-t) is defined as the area under the plasma concentration versus time curve calculated from time 0 to the last measurable sampling time point, t, computed using the linear trapezoidal rule. Blood samples will be collected at indicated timepoints for the analysis of AUC(0-t).

    Time frame: Pre-dose (within 1 hour prior to dosing) and at 5,10,15,30,45 minutes and 1,1.25,1.5,1.75,2,2.25,2.5,2.75,3,3.25,3.5,3.75,4,4.25,4.5,4.75,5,5.5,6,8,10,12,16 and 24 hours post-dose on Day 1 in each treatment period (each treatment period is 3 days)

  5. Area Under the Plasma Concentration Versus Time Curve Calculated From Time 0 to Infinity (AUC[0-inf]) for Test Product Under Fed Conditions Compared to Fasted Conditions

    AUC(0-inf) is defined as the area under the plasma concentration versus time curve calculated from time 0 to infinity. AUC(0-inf) = AUC(0-t) + C(t)/λz where C(t) is the concentration at the last measurable sampling time point and λz is the terminal elimination rate constant. Blood samples will be collected at indicated timepoints for the analysis of AUC(0-inf).

    Time frame: Pre-dose (within 1 hour prior to dosing) and at 5,10,15,30,45 minutes and 1,1.25,1.5,1.75,2,2.25,2.5,2.75,3,3.25,3.5,3.75,4,4.25,4.5,4.75,5,5.5,6,8,10,12,16 and 24 hours post-dose on Day 1 in each treatment period (each treatment period is 3 days)

Secondary outcomes

  1. AUC(0-inf) for Test and Reference Products

    AUC(0-inf) is defined as the area under the plasma concentration versus time curve calculated from time 0 to infinity. AUC(0-inf) = AUC(0-t) + C(t)/λz where C(t) is the concentration at the last measurable sampling time point and λz is the terminal elimination rate constant. Blood samples will be collected at indicated timepoints for the analysis of AUC(0-inf).

    Time frame: Pre-dose (within 1 hour prior to dosing) and at 5,10,15,30,45 minutes and 1,1.25,1.5,1.75,2,2.25,2.5,2.75,3,3.25,3.5,3.75,4,4.25,4.5,4.75,5,5.5,6,8,10,12,16 and 24 hours post-dose on Day 1 in each treatment period (each treatment period is 3 days)

  2. Percentage of AUC(0-inf) Obtained by Extrapolation (%AUCex) for Test and Reference Products

    %AUCex is defined as the percentage of AUC(0-inf) obtained by extrapolation, calculated as (1-\[AUC0-t/AUC0-inf\]) \*100. Blood samples will be collected at indicated timepoints for the analysis of %AUCex.

    Time frame: Pre-dose (within 1 hour prior to dosing) and at 5,10,15,30,45 minutes and 1,1.25,1.5,1.75,2,2.25,2.5,2.75,3,3.25,3.5,3.75,4,4.25,4.5,4.75,5,5.5,6,8,10,12,16 and 24 hours post-dose on Day 1 in each treatment period (each treatment period is 3 days)

  3. Terminal Elimination Rate Constant (λz) for Test and Reference Products

    λz is defined as the terminal elimination rate constant computed as the negative of the slope of the regression line of ln(C\[t\]) on time. The regression should generally involve at least 3 consecutive measurable concentrations that decrease over time excluding Cmax. Blood samples will be collected at indicated timepoints for the analysis of λz.

    Time frame: Pre-dose (within 1 hour prior to dosing) and at 5,10,15,30,45 minutes and 1,1.25,1.5,1.75,2,2.25,2.5,2.75,3,3.25,3.5,3.75,4,4.25,4.5,4.75,5,5.5,6,8,10,12,16 and 24 hours post-dose on Day 1 in each treatment period (each treatment period is 3 days)

  4. Time of the Maximum Observed Post-dose Concentration (tmax) for Test and Reference Products

    Blood samples will be collected at indicated timepoints for the analysis of tmax.

    Time frame: Pre-dose (within 1 hour prior to dosing) and at 5,10,15,30,45 minutes and 1,1.25,1.5,1.75,2,2.25,2.5,2.75,3,3.25,3.5,3.75,4,4.25,4.5,4.75,5,5.5,6,8,10,12,16 and 24 hours post-dose on Day 1 in each treatment period (each treatment period is 3 days)

  5. Elimination Half-life (t1/2) for Test and Reference Products

    t1/2 is defined as the elimination half-life computed as t1/2 = ln(2)/λz where λz is the terminal elimination rate constant. Blood samples will be collected at indicated timepoints for the analysis of t1/2.

    Time frame: Pre-dose (within 1 hour prior to dosing) and at 5,10,15,30,45 minutes and 1,1.25,1.5,1.75,2,2.25,2.5,2.75,3,3.25,3.5,3.75,4,4.25,4.5,4.75,5,5.5,6,8,10,12,16 and 24 hours post-dose on Day 1 in each treatment period (each treatment period is 3 days)

  6. Apparent Volume of Distribution (Vz/F) for Test and Reference Products

    Vz/F is defined as the apparent volume of distribution, as calculated by the dose administered/(λz \*AUC0-inf) where λz is the terminal elimination rate constant and AUC(0-inf) is the area under the plasma concentration versus time curve calculated from time 0 to infinity. Blood samples will be collected at indicated timepoints for the analysis of Vz/F.

    Time frame: Pre-dose (within 1 hour prior to dosing) and at 5,10,15,30,45 minutes and 1,1.25,1.5,1.75,2,2.25,2.5,2.75,3,3.25,3.5,3.75,4,4.25,4.5,4.75,5,5.5,6,8,10,12,16 and 24 hours post-dose on Day 1 in each treatment period (each treatment period is 3 days)

  7. Apparent Total Clearance (Cl/F) for Test and Reference Products

    Cl/F is defined as the apparent total clearance, as calculated by the dose administered/AUC0-inf where AUC(0-inf) is the area under the plasma concentration versus time curve calculated from time 0 to infinity. Blood samples will be collected at indicated timepoints for the analysis of Cl/F.

    Time frame: Pre-dose (within 1 hour prior to dosing) and at 5,10,15,30,45 minutes and 1,1.25,1.5,1.75,2,2.25,2.5,2.75,3,3.25,3.5,3.75,4,4.25,4.5,4.75,5,5.5,6,8,10,12,16 and 24 hours post-dose on Day 1 in each treatment period (each treatment period is 3 days)

  8. Number of Participants Reporting Ease of Swallowing: Categorical Response

    Immediately after dosing, participants will be asked to evaluate the ease of swallowing to assess the acceptability of each treatment. Participants will be asked to provide a categorical response (Agree/Disagree) to the question "Do you agree or disagree that the product is easy to swallow?".

    Time frame: Post Dose on Day 1 in each treatment period (each treatment period is 3 days)

  9. Number of Participants Reporting Ease of Swallowing on a 5-Point Ordinal Scale

    Immediately after dosing, participants will be asked to rank the ease of swallowing of each product on a 5-point ordinal scale with scores ranging from 1 to 5 where 1=not easy to swallow; 2=somewhat easy to swallow; 3=average to swallow; 4=above average to swallow; 5=very easy to swallow. Higher score indicates more ease in swallowing.

    Time frame: Post Dose on Day 1 in each treatment period (each treatment period is 3 days)

07

Study locations

1 site
  • Novum Pharmaceutical Research Services
    Las Vegas, Nevada 89121, United States
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trial-register@haleon.com

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2025 to primary completion in Feb 2026, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2025
First posted
Jan 15, 2026
StartActual
Dec 17, 2025
Primary completionActual
Feb 3, 2026
CompletionActual
Feb 3, 2026
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07345130
Lead sponsor
HALEON
Responsible party
Sponsor
First posted
Jan 15, 2026
Start date
Dec 17, 2025
Primary completion
Feb 3, 2026
Completion
Feb 3, 2026
Last update
Sep 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion